Last reviewed · How we verify
Bevacizumab-containing regimen
Bevacizumab-containing regimens work by inhibiting angiogenesis through the blockade of vascular endothelial growth factor A (VEGF-A).
Bevacizumab-containing regimens work by inhibiting angiogenesis through the blockade of vascular endothelial growth factor A (VEGF-A). Used for Metastatic colorectal cancer, Non-small cell lung cancer, Breast cancer.
At a glance
| Generic name | Bevacizumab-containing regimen |
|---|---|
| Also known as | Avastin |
| Sponsor | Hoffmann-La Roche |
| Drug class | Angiogenesis inhibitor |
| Target | VEGF-A |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
This is achieved by binding to VEGF-A, preventing its interaction with its receptor, and subsequently inhibiting the formation of new blood vessels that tumors need to grow and metastasize. This mechanism is particularly effective in treating various types of cancer.
Approved indications
- Metastatic colorectal cancer
- Non-small cell lung cancer
- Breast cancer
- Glioblastoma
- Renal cell carcinoma
Common side effects
- Hypertension
- Nausea
- Fatigue
- Headache
- Diarrhea
Key clinical trials
- SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety (PHASE2)
- Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant (PHASE4)
- A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene. (PHASE1)
- Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas
- Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis (PHASE1, PHASE2)
- A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. (PHASE1)
- Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer (PHASE3)
- A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bevacizumab-containing regimen CI brief — competitive landscape report
- Bevacizumab-containing regimen updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI